Director/Board Member at Rallybio Corp., Discover Ron Hunt's known position history, network and 100 relationships. Find out about his known public assets.
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q4 2023 Earnings Call Transcript February 28, 2024 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $0.28, expectations were $-0.3. Fulgent Genetics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings and welcome to […]
For El Monte-based clinical diagnostic testing company Fulgent Genetics Inc., the Covid testing surge that catapulted the company from $32 million in annual revenue to the doorstep of $1 billion in just two years has now all but ended.
/PRNewswire/ Synthetica Bio, a privately held healthcare technology company developing an enterprise-grade, generative artificial intelligence (GenAI).
The company is continuing its Phase 1 clinical trial evaluating the efficacy of FID-007 in treating various types of cancer. See why FLGT stock is a Hold.